Arrowhead Pharmaceuticals Inc Key Opinion Leader Webinar on ARO-ANG3 Transcript
Good afternoon, and welcome to Part 2 of the 2-part KOL Webinar series hosted by Arrowhead Pharmaceuticals. (Operator Instructions) As a reminder, this conference is being recorded, and a replay will be made available on the Arrowhead website following the event.
I would now like to turn the call over to your host, Vince Anzalone, Vice President of Investor Relations at Arrowhead Pharmaceuticals. Please go ahead, sir.
Thank you, Sara, and thanks, everybody, for joining us again today. And for those that missed it, we had another webinar yesterday to go over ARO-APOC3 and today, we'll be talking about ARO-ANG3.
So next slide, please. Next slide, please. Okay. Just a reminder, we will be making forward-looking statements today. So please refer to the risk factors in our SEC filings.
Next slide, please. We have a really good panel today, and we're very happy to have, again, Dr. Ira Goldberg from the New York University Grossman School of Medicine, where he is the Clarissa and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |